Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03826901 |
Recruitment Status :
Completed
First Posted : February 1, 2019
Last Update Posted : November 26, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atopic Dermatitis | Drug: delgocitinib | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 46 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis |
Actual Study Start Date : | February 20, 2019 |
Actual Primary Completion Date : | October 29, 2021 |
Actual Study Completion Date : | October 29, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Part 1: adults and adolescents (12 years and above)
Delgocitinib cream (dosage: A mg/g).
|
Drug: delgocitinib
Cream for topical application
Other Name: LEO 124249 |
Experimental: Part 2: children (2-11 years)
Delgocitinib cream (dosage: B mg/g).
|
Drug: delgocitinib
Cream for topical application
Other Name: LEO 124249 |
- Adverse events (AEs) [ Time Frame: Week 0 to Week 8 ]Number of AEs and number of subjects with AEs
- PK parameter - Cmax [ Time Frame: at Day 8 ]Cmax
- PK parameter - AUC [ Time Frame: at Day 8 ]AUC
- PK parameter - tmax [ Time Frame: at Day 8 ]tmax
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion criteria (Part 1: adults and adolescents; 12 years and above)
- Diagnosis of atopic dermatitis (AD) as defined by the Hanifin and Rajka (1980) criteria for AD
- Age 12 years and above at baseline
- AD involvement of 25-50% treatable body surface area (BSA) at screening and at baseline
- Moderate to severe AD (Validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of at least 3) at screening and at baseline
Key Inclusion criteria (Part 2: children; 2-11 years)
- Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD
- Age 2-11 years at baseline
- History of AD for at least 3 months (children aged 2-5 years), and at least 12 months (children aged 6-11 years)
- AD involvement of ≥35% treatable BSA at screening and at baseline
- Moderate to severe AD (vIGA-AD score of at least 3) at screening and at baseline
Key Exclusion criteria (Part 1 and 2: subjects aged 2 years and above)
- Active dermatologic conditions that may interfere with the diagnosis of AD
- Use of tanning beds or phototherapy within 4 weeks prior to baseline
- Systemic treatment with immunosuppressive/modulating drugs or corticosteroids within 4 weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to baseline
- Treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), topical phosphodiesterase-4, or oral antibiotics within 1 week prior to baseline
- Clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline
- Any disorder, which is not stable, and in the investigator's opinion could affect the safety of the subject, influence the results of the trial or impede the subject's ability to complete the trial
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03826901
United States, Alabama | |
LEO Pharma investigational site | |
Birmingham, Alabama, United States, 35209 | |
United States, Arizona | |
LEO Pharma investigational site | |
Phoenix, Arizona, United States, 85006 | |
United States, California | |
LEO Pharma investigational site | |
Fountain Valley, California, United States, 92708 | |
LEO Pharma investigational site | |
Irvine, California, United States, 92697 | |
LEO Pharma investigational site | |
Los Angeles, California, United States, 90027 | |
United States, Colorado | |
LEO Pharma investigational site | |
Centennial, Colorado, United States, 80112 | |
United States, Connecticut | |
LEO Pharma investigational site | |
New Haven, Connecticut, United States, 06519 | |
United States, Indiana | |
LEO Pharma investigational site | |
Indianapolis, Indiana, United States, 46250 | |
United States, Michigan | |
LEO Pharma investigational site | |
Ypsilanti, Michigan, United States, 48197 | |
United States, Oklahoma | |
LEO Pharma investigational site | |
Tulsa, Oklahoma, United States, 74136 | |
United States, Oregon | |
LEO Pharma investigational site | |
Medford, Oregon, United States, 97504 | |
United States, Texas | |
LEO Pharma investigational site | |
San Antonio, Texas, United States, 78218 | |
Canada, Alberta | |
LEO Pharma investigational site | |
Red Deer, Alberta, Canada, 46-37535 | |
Canada, Ontario | |
LEO Pharma investigational site | |
Hamilton, Ontario, Canada, L8S 1G5 | |
Canada, Quebec | |
LEO Pharma investigational site | |
Montreal, Quebec, Canada, H3T 1C5 | |
LEO Pharma investigational site | |
Montréal, Quebec, Canada, H2K 4L5 |
Study Director: | Medical Expert | LEO Pharma |
Responsible Party: | LEO Pharma |
ClinicalTrials.gov Identifier: | NCT03826901 |
Other Study ID Numbers: |
LP0133-1181 |
First Posted: | February 1, 2019 Key Record Dates |
Last Update Posted: | November 26, 2021 |
Last Verified: | November 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | De-identified IPD can be made available to researchers in a closed environment for a specified period of time. Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Clinical Study Report (CSR) |
Time Frame: | Data is available to request after approval of the studied indication. |
URL: | http://leopharmatrials.com/for-professionals |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
adults, pediatric |
Dermatitis, Atopic Dermatitis Eczema Skin Diseases Skin Diseases, Genetic |
Genetic Diseases, Inborn Skin Diseases, Eczematous Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |